Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Related Articles by Review for PubMed (Select 17848673)

1.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

2.

High-grade prostate cancer and finasteride.

Lebdai S, Bigot P, Azzouzi AR.

BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review.

PMID:
19930174
3.
4.

Prostate cancer prevention and finasteride.

D'Amico AV, Barry MJ.

J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review.

PMID:
17070238
5.

Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.

Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.

J Clin Oncol. 2005 Mar 20;23(9):1911-20. Review.

PMID:
15774783
6.

The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.

Reed AB, Parekh DJ.

Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29. Review.

PMID:
19318950
7.

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG.

J Urol. 2005 Dec;174(6):2098-104. Review.

PMID:
16280736
8.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
9.

Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice.

Goetzl MA, Holzbeierlein JM.

Nat Clin Pract Urol. 2006 Aug;3(8):422-9. Review.

PMID:
16902518
10.

Effect of finasteride on risk of prostate cancer: how little we really know.

Rubin MA, Kantoff PW.

J Cell Biochem. 2004 Feb 15;91(3):478-82. Review.

PMID:
14755678
11.

The Prostate Cancer Prevention Trial: current status.

Higgins B, Thompson IM.

J Urol. 2004 Feb;171(2 Pt 2):S15-7; discussion S8. Review.

PMID:
14713747
12.
13.

Should finasteride be used to prevent prostate cancer?

Fleshner N, Kulkarni G.

Curr Treat Options Oncol. 2006 Sep;7(5):346-54. Review.

PMID:
16904051
14.

A review of phase III clinical trials of prostate cancer chemoprevention.

Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK.

Ann R Coll Surg Engl. 2007 Apr;89(3):207-11. Review.

15.

Does finasteride alter the pathology of the prostate and cancer grading?

Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R.

Clin Prostate Cancer. 2004 Mar;2(4):228-35. Review.

PMID:
15072606
16.

The finasteride prostate cancer prevention trial (PCPT)--what have we learned?

Mellon JK.

Eur J Cancer. 2005 Sep;41(13):2016-22. Review.

PMID:
16061372
17.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
18.

Pharmacological approaches to reducing the risk of prostate cancer.

Rittmaster RS, Fleshner NE, Thompson IM.

Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5. Review.

PMID:
19200641
19.

Screening for prostate cancer: opportunities for prevention.

Thompson IM, Coltman CA.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):4-10; discussion 10-1. Review.

PMID:
8725886
20.

Grading prostate cancer.

Bostwick DG.

Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S38-56. Review.

PMID:
7524306
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk